Big pharma Q3 earnings roll out as FDA launches rare-disease initiative and uniQure's Huntington's gene therapy enters review
Over the past week, a dozen major pharmaceutical companies reported third‑quarter results, including AstraZeneca, Biogen, GSK, Bristol Myers Squibb, Merck, Sanofi, AbbVie and Regeneron.
Pfizer posted flat revenue but beat expectations, while Eli Lilly generated higher than expected earnings driven by its tirzepatide franchise, prompting analysts to question the company's growth forecasts.
Alnylam’s earnings call was tougher despite a 59 % revenue rise in its transthyretin franchise, with CEO Yvonne Greenstreet noting performance challenges.
The FDA announced a new initiative to speed rare‑disease drug development, and HHS approved the compounding of six unapproved peptides. In parallel, the agency accepted uniQure’s Huntington’s disease gene therapy for formal review.
This writeup was produced by pharmadog from original reporting by BioSpace.
Original headline: “Q3 earnings roll on, FDA pushes rare disease, uniQure’s Huntington’s therapy reaches review”
read at BioSpace ↗
comments(0)
5-min edit window · permanent after that